Novel three-step pretargeted radioimmunotherapy offers safe, effective treatment
Researchers at Memorial Sloan Kettering Cancer Center in New York City and Massachusetts Institute of Technology in Boston have developed a new, three-step system that uses nuclear medicine to target and eliminate colorectal cancer. In this study with a mouse model, researchers achieved a 100-percent cure rate—without any treatment-related toxic effects. The study is reported in the November featured article in The Journal of Nuclear Medicine.
Until now, radioimmunotherapy (targeted therapy) of solid tumors using antibody-targeted radionuclides has had limited therapeutic success. “This research is novel because of the benchmarks reached by the treatment regimen, in terms of curative tumor doses, with non-toxic secondary radiation to the body’s normal tissues,” explains Steven M. Larson, MD, and Sarah Cheal, PhD, of Memorial Sloan Kettering Cancer Center. “The success in murine tumor models comes from the unique quality of the reagents developed by our group, and the reduction to practice methodology, including a theranostic approach that can be readily transferred, we believe, to patients.”
Theranostics, a term derived from therapy and diagnostics, is the use of a single agent to both diagnose and treat disease. The theranostic agent first finds the cancer cells, then destroys them, leaving healthy cells unharmed—minimizing side effects and improving quality of life for patients.
In this study, the glycoprotein A33 (GPA33), an antigen found on over 95 percent of primary and metastatic human colorectal cancers, was targeted with a bispecific antibody for A33 tumor antigen and a second antibody for a small-molecule radioactive hapten, a complex of lutetium-177 (177Lu) and S-2-(4-aminobenzyl)1,4,7,10-tetraazacyclododecane tetra-acetic acid (177Lu-DOTA-Bn).
The DOTA-pretargeted radioimmunotherapy (PRIT) strategy was tested on a mouse model. In randomly selected mice undergoing treatment, serial SPECT/CT imaging was used to monitor treatment response and calculate radiation-absorbed doses to tumors. All the DOTA-PRIT–treated animals tolerated the treatment well, and all 9 assessed mice had no trace of cancer remaining upon microscopic examination. There was also no detectable radiation damage to critical organs, including bone marrow and kidneys.
The 100-percent cure rate in the mouse model is a promising preliminary finding that suggests that anti-GPA33-DOTA-PRIT will be a potent radioimmunotherapy regimen for GPA33-positive colorectal cancer tumors in humans.
According to the Centers for Disease Control and Prevention, colorectal cancer is the third most common cancer affecting both men and women. Each year, approximately 140,000 new cases are diagnosed in the United States and 50,000 people die of the disease.
The applications of this nuclear medicine treatment protocol could extend to other cancers as well. Larson and Cheal state, “If clinically successful, our approach will expand the repertoire of effective treatments for oncologic patients. The system is designed as a ‘plug and play’ system, which allows for the use of many fine antibodies targeting human tumor antigens and is applicable, in principle, to virtually all solid and liquid tumors in man.” They add, “There is a huge unmet need in oncology, especially for the solid tumors, for curative treatments for advanced disease. This includes, colon, breast, pancreas, melanoma, lung, and esophageal, to name a few.”
The Latest on: Colorectal cancer
- ‘Aren’t I Too Young?’ How MSK Helps People under 50 with Colorectal and GI Cancerson March 8, 2021 at 3:34 pm
Learn more about the first facility in the world devoted to the specific needs of colorectal cancer patients under the age of 50.
- Continuing the conversation around colorectal canceron March 8, 2021 at 2:52 pm
When people see Kevin Hays they always tell him he doesn't look like he has cancer. But he's been battling with colorectal cancer for seven years.
- Colon cancer on the increase for young menon March 8, 2021 at 2:00 pm
There's been an alarming trend in healthy young men in their 20's, 30's and 40's. A steady increase in colon cancer. Dr. Martin Luchtefeld colon cancer specialist with Spectrum Health says while more ...
- In-Vitro Colorectal Cancer Screening Tests Market Share, Size to register significant growth over 2017-2024 - Industry Analysison March 8, 2021 at 11:57 am
Increasing incidences of colorectal cancer across the globe, in tandem with rising geriatric population who is highly susceptible to colorectal cancer is driving the growth of worldwide in-vitro ...
- LVHN partnering with Allentown grocery store to offer free delivery, raise awareness of colorectal canceron March 8, 2021 at 8:42 am
To raise awareness of March being National Colorectal Cancer Month. Lehigh Valley Health Network will sponsor free grocery delivery from downtown Allentown's Radish Republic grocery store for the week ...
- MRI-based clinical-radiomics model predicts tumor response before treatment in locally advanced rectal canceron March 8, 2021 at 6:19 am
Neoadjuvant chemo-radiotherapy (CRT) followed by total mesorectal excision (TME) represents the standard treatment for patients with locally advanced (≥ T3 or N+) rectal cancer (LARC). Approximately ...
- Bringing Awareness to Colorectal Canceron March 8, 2021 at 5:15 am
Simple screenings are the key to preventing diseases like colorectal cancer, the third most commonly diagnosed cancer and the second leading cause of cancer deaths among Americans. We sit down with ...
- Partial hepatectomy enhances the growth of CC531 rat colorectal cancer cells both in vitro and in vivoon March 8, 2021 at 5:07 am
Partial hepatectomy (PHx) is the gold standard for the treatment of colorectal cancer liver metastases. However, after removing a substantial amount of hepatic tissue, growth factors are released to ...
- Colon cancer screenings: ‘The only wrong option is to do nothing,’ doctor sayson March 8, 2021 at 1:00 am
Colorectal cancer is the second-leading cause of cancer death in the U.S. for men and women combined. “The five-year survival rate for colorectal cancer is 90%, if it’s caught at an early stage, 90%.
- Craig Melvin honors his late brother to help raise awareness of colon canceron March 5, 2021 at 6:19 pm
TODAY’s Craig Melvin lost his older brother Lawrence to colon cancer. Marking Colorectal Cancer Awareness Month, Craig talks about his loss as his younger brother Ryan gets a colonoscopy. “He was ...
via Google News and Bing News